Literature DB >> 17266153

Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population.

Youn K Shim1, Robert F Vogt, Dan Middleton, Fatima Abbasi, Barbara Slade, Kyung Y Lee, Gerald E Marti.   

Abstract

BACKGROUND: Monoclonal B-cells can be detected in the peripheral blood of some adults without B-cell malignancies, a condition recently termed monoclonal B-cell lymphocytosis (MBL). The risk of individuals with MBL progressing to a B-cell malignancy is unknown. Polyclonal B-cell lymphocytosis (PCBL) has not been systematically studied in the general population.
METHODS: We obtained lymphocyte subset counts on 1,926 residential adults aged 40-76 years in a series of environmental health studies between 1991 and 1994. We then conducted two follow-ups in 1997 and 2003 on consenting participants with B-cell lymphocytosis, which included nine participants with MBL. To ascertain the clinical implications of MBL, we reviewed medical records and death certificates.
RESULTS: The overall prevalence of MBL was 0.57% (11/1,926): nine cases at baseline and two additional cases identified at follow-up. Two (19%) MBL cases subsequently developed a B-cell malignancy; MBL persisted in the remaining nine cases (81%). All PCBL cases where no clone emerged regressed to normal B-cell counts over the follow-up period. MBL was significantly more frequent in residents near a hazardous waste site than in the control populations (age-adjusted OR 6.2; 95%CI 1.1-36.2).
CONCLUSION: MBL confers an elevated risk for developing a B-cell malignancy, although it occurs only in a minority of cases. PCBL is most often a transient state, but a monoclonal population can emerge and persist. Prospective studies are needed to distinguish stable from progressive forms of B-cell lymphocytosis and to clarify the etiologic role of environmental exposures. Published 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17266153     DOI: 10.1002/cyto.b.20174

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  22 in total

1.  Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.

Authors:  Lynn R Goldin; Mark C Lanasa; Susan L Slager; James R Cerhan; Celine M Vachon; Sara S Strom; Nicola J Camp; Logan G Spector; Jose F Leis; Vicki A Morrison; Martha Glenn; Kari G Rabe; Sara J Achenbach; Sallie D Algood; Fatima Abbasi; Laura Fontaine; Michelle Yau; Laura Z Rassenti; Neil E Kay; Timothy G Call; Curtis A Hanson; J Brice Weinberg; Gerald E Marti; Neil E Caporaso
Journal:  Br J Haematol       Date:  2010-08-25       Impact factor: 6.998

Review 2.  Prevalence of monoclonal B-cell lymphocytosis: a systematic review.

Authors:  Youn K Shim; Dannie C Middleton; Neil E Caporaso; Jane M Rachel; Ola Landgren; Fatima Abbasi; Elizabeth S Raveche; Andy C Rawstron; Alberto Orfao; Gerald E Marti; Robert F Vogt
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

3.  Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding.

Authors:  Youn K Shim; Jane M Rachel; Paolo Ghia; Jeff Boren; Fatima Abbasi; Antonis Dagklis; Geri Venable; Jiyeon Kang; Heba Degheidy; Fred V Plapp; Robert F Vogt; Jay E Menitove; Gerald E Marti
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

Review 4.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Authors:  T D Shanafelt; P Ghia; M C Lanasa; O Landgren; A C Rawstron
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

Review 5.  Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Authors:  Paolo Strati; Tait D Shanafelt
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 6.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 7.  Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).

Authors:  Andy C Rawstron; Tait Shanafelt; Mark C Lanasa; Ola Landgren; Curtis Hanson; Alberto Orfao; Peter Hillmen; Paolo Ghia
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 8.  Monoclonal B cell lymphocytosis: clinical and population perspectives.

Authors:  Neil E Caporaso; Gerald E Marti; Ola Landgren; Elizabeth Azzato; J Brice Weinberg; Lynn Goldin; Tait Shanafelt
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 9.  Prevalence, clinical aspects, and natural history of IgM MGUS.

Authors:  Mary L McMaster; Ola Landgren
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

10.  Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Neil E Kay; Kari G Rabe; Timothy G Call; Clive S Zent; Kami Maddocks; Greg Jenkins; Diane F Jelinek; William G Morice; Justin Boysen; Susan Schwager; Deborah Bowen; Susan L Slager; Curtis A Hanson
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.